Trial reportEuropean journal of cancer (Oxford, England : 1990)2014
Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib.
Trial report in European journal of cancer (Oxford, England : 1990), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 32 citations in OpenAlex.
- Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial.The oncologist · 2019Trial
- Predictive performance of [Quantitative imaging in medicine and surgery · 2024Article
- CT features combined with RECIST 1.1 criteria improve progression assessments of sunitinib-treated gastrointestinal stromal tumors.European radiology · 2024Article
- Pan-Canadian consensus recommendations for GIST management in high- and low-throughput centres across Canada.Therapeutic advances in medical oncology · 2024Review
- Article
- Progress in determining response to treatment in gastrointestinal stromal tumor.Expert review of anticancer therapy · 2020Review
- RECIST and CHOI criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter study.Cancer imaging : the official publication of the International Cancer Imaging Society · 2019Article
- Micromanagement of drug-resistant advanced gastrointestinal stromal tumors: regorafenib-new ammunition in battling exon 17 mutations.Translational gastroenterology and hepatology · 2018Article
- Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients.Scientific reports · 2017Article
- Imaging therapy response of gastrointestinal stromal tumors (GIST) with FDG PET, CT and MRI: a systematic review.Clinical and translational imaging · 2017Review
- Comparison of the RECIST 1.0 and RECIST 1.1 in patients treated with targeted agents: a pooled analysis and review.Oncotarget · 2016Review
- The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2016Review
- Article
- Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials.Oncotarget · 2015Review
- RECIST 1.1 compared with RECIST 1.0 in patients with advanced renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.AJR. American journal of roentgenology · 2015Article
- Clinical Implication of Anti-Angiogenic Effect of Regorafenib in Metastatic Colorectal Cancer.PloS one · 2015Article
- Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program.Clinical sarcoma research · 2014Article
- Gastrointestinal Stromal Tumor (GIST) from esophagus to anorectum - diagnosis, response evaluation and surveillance on computed tomography (CT) scan.The Indian journal of radiology & imagingArticle
- Update on Gastrointestinal Stromal Tumors for Radiologists.Korean journal of radiologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
purposeTo compare performance of various tumour response criteria (TRCs) in assessment of regorafenib activity in patients with advanced gastrointestinal stromal tumour (GIST) with prior failure of imatinib and sunitinib.
methodsTwenty participants in a phase II trial received oral regorafenib (median duration 47 weeks; interquartile range (IQR) 24-88) with computed tomography (CT) imaging at baseline and every two months thereafter. Tumour response was prospectively determined on using Response Evaluation Criteria in Solid Tumours (RECIST) 1.1, and retrospectively reassessed for comparison per RECIST 1.0, World Health Organization (WHO) and Choi criteria, using the same target lesions. Clinical benefit rate [CBR; complete or partial response (CR or PR) or stable disease (SD)≥16 weeks] and progression-free survival (PFS) were compared between various TRCs using kappa statistics. Performance of TRCs in predicting overall survival (OS) was compared by comparing OS in groups with progression-free intervals less than or greater than 20 weeks by each TRC using c-statistics.
resultsPR was more frequent by Choi (90%) than RECIST 1.1, RECIST 1.0 and WHO (20% each), however, CBR was similar between various TRCs (overall CBR 85-90%, 95-100% agreement between all TRC pairs). PFS per RECIST 1.0 was similar to RECIST 1.1 (median 44 weeks versus 58 weeks), and shorter for WHO (median 34 weeks) and Choi (median 24 weeks). With RECIST 1.1, RECIST 1.0 and WHO, there was moderate concordance between PFS and OS (c-statistics 0.596-0.679). Choi criteria had less favourable concordance (c-statistic 0.506).
conclusionsRECIST 1.1 and WHO performed somewhat better than Choi criteria as TRC for response evaluation in patients with advanced GIST after prior failure on imatinib and sunitinib.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.